ACIP votes 8–3 to end universal Hep B birth dose; separate 6–4–1 vote backs post‑shot antibody testing
At a contentious Dec. meeting, the HHS‑appointed Advisory Committee on Immunization Practices voted 8–3 to end the universal hepatitis B birth‑dose—limiting routine immediate vaccination to infants of HBV‑positive mothers and leaving other cases to clinician‑parent decision‑making—and separately voted 6–4‑1 to recommend post‑vaccination antibody testing to identify infants who might require fewer than three doses. The recommendations, which must be approved by acting CDC director Jim O’Neill, drew sharp criticism from pediatric and infectious‑disease experts and public‑health groups who warn the change could lead to hundreds or thousands more infant infections given screening gaps and the vaccine’s decades‑long role in nearly eliminating pediatric hepatitis B.
📌 Key Facts
- ACIP voted 8–3 to end the universal hepatitis B birth‑dose recommendation and instead to recommend a birth dose only for infants born to HBV‑positive mothers; for infants of HBV‑negative or unknown mothers the panel advised parent‑physician shared decision‑making. The recommendation still requires approval by acting CDC director Jim O’Neill.
- In a separate vote the panel voted 6–4‑1 to recommend measuring infants’ hepatitis B antibody levels after each shot to determine whether fewer than three doses might be sufficient, a change CDC officials warned would depart from the evidence base tested in three‑dose trials.
- The ACIP changes followed a leadership and membership overhaul by HHS Secretary Robert F. Kennedy Jr. (who fired and replaced the prior 17‑member committee, appointed the current members and named a new chair), and the meeting was contentious: votes were delayed amid changing language, nonvoting liaisons and many outside experts criticized the process and membership composition.
- Medical evidence cited in coverage: a birth dose given within 24 hours is up to ~90% effective at preventing mother‑to‑child transmission, and completion of the three‑dose series confers roughly 98–99% immunity lasting decades; infants infected at birth face ~90% risk of chronic infection and about a 25% lifetime risk of premature death from HBV‑related disease (cirrhosis, liver cancer).
- Public‑health and operational concerns highlighted: hepatitis B can be transmitted non‑sexually (household items, shared razors/toothbrushes) and can survive on surfaces up to a week; many people with HBV are unaware (coverage cited estimates ranging from ~640,000 chronic adults to ~2.4 million people with HBV), about 16% of pregnant women are not screened, and maternal tests have a small false‑negative rate—factors that supporters of the birth dose say make it an important safety net.
- Modeling and preprint estimates presented to and cited by experts warn the policy change could cause substantial harms — delaying the birth dose by two months was estimated to cause at least ~1,400 additional infant infections per year (with larger increases if delayed to older ages), and experts warned cases and chronic infections could rise if the change is finalized.
- Major pediatric and infectious‑disease voices (including the American Academy of Pediatrics and prominent vaccine scientists) publicly opposed the change and said they will continue recommending the birth dose; the decision also drew sharp political reaction — some Republican leaders praised the vote and called for broader schedule reviews while others urged the acting CDC director not to adopt it.
- If the CDC acting director accepts ACIP’s recommendation, it could affect future CDC guidance, state vaccine requirements and insurer coverage, but states retain authority over immunization mandates.
📊 Relevant Data
In the United States, more than 50% of people living with chronic hepatitis B are of Asian, Pacific Islander, or African descent.
Hepatitis B Facts and Figures — Hepatitis B Foundation
The prevalence of chronic hepatitis B is estimated at 3.0% among Asian American individuals compared with 0.1% among non-Hispanic White individuals in the United States.
Racial Disparities in Treatment and Outcomes of Chronic Hepatitis B Virus Infection — JAMA Network Open
In 2022, the rate of reported chronic hepatitis B cases was 20.1 per 100,000 among non-Hispanic Asian/Pacific Islanders, compared to 4.0 per 100,000 among non-Hispanic Blacks, 1.3 per 100,000 among non-Hispanic Whites, and 2.0 per 100,000 among Hispanics in the United States.
Table 2.6 – Chronic Hepatitis B: Case Rates by Demographics — Centers for Disease Control and Prevention
📰 Sources (19)
Vaccine vote signals turbulence for immunization policy, public trust
New information:
- CBS reports all current ACIP members were appointed by HHS Secretary Robert F. Kennedy Jr.
- HHS spokesperson Emily Hilliard defended the panel’s process, stating ACIP “reviews all evidence presented and issues recommendations based on evidence and sound judgment to best protect America’s children.”
- An independent review by the Vaccine Integrity Project (housed at the University of Minnesota’s CIDRAP) evaluated 400+ studies and warned in a public comment that delaying the birth dose could increase avoidable HBV infections and undermine progress.
Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
New information:
- Former FDA commissioner Scott Gottlieb publicly criticizes the ACIP decision and refutes President Trump’s claim that Hep B is only sexually/needle transmitted, stressing high risk of perinatal transmission.
- Gottlieb cites a ~2% false‑negative rate for maternal hepatitis B tests and says this could translate to at least 1,000 newborn infections if the birth dose is delayed.
- He references a modeling estimate that about 1,400 infants could contract hepatitis B in the first year under the new guidance.
- Gottlieb reiterates risk statistics (e.g., ~90% of infected newborns develop chronic infection; ~25% die of sequelae) and says the birth‑dose plus series is ~99% effective at preventing chronic infection.
- Operational concern raised: many mothers are not tested, test results may not be checked, and relying solely on maternal screening is unsafe.
Fact-checking the CDC panel’s reasons for dropping universal newborn hepatitis B vaccine recommendation
New information:
- CDC estimates about 640,000 U.S. adults have chronic hepatitis B, roughly half unaware of their infection, underscoring hidden exposure risk to infants.
- Hepatitis B virus can survive on surfaces for up to a week; small amounts of dried blood on shared household items (nail clippers, razors, toothbrushes) can transmit infection.
- Before universal newborn vaccination, only about half of HBV infections in children under 10 were perinatal; many were acquired via household/community exposure.
- Infants infected with HBV face ~90% risk of chronic infection and about 25% premature mortality from HBV-related disease (cirrhosis, liver cancer); no cure exists.
- Expert quotes: Dr. James Campbell said the U.S. once saw 18,000–20,000 HBV-positive births annually with a quarter progressing to liver cancer, now 'almost none' due to vaccination; ACIP member Dr. H. Cody Meissner stated, 'This disease has become a victim of the vaccine.'
Under RFK Jr., U.S. Vaccine Policy Arrives at a ‘Defining Moment’
New information:
- HHS Secretary Robert F. Kennedy Jr. previously fired all 17 ACIP members six months ago and installed replacements as part of a vaccine‑policy overhaul.
- CDC acting director Jim O’Neill must decide whether to accept the recommendation; the guidance language tells HBV‑negative pregnant women to consult providers and decide 'when or if' their newborns will receive the hepatitis B vaccine.
- The committee formed a working group to reconsider the entire childhood vaccine schedule and began with a presentation by Aaron Siri, who has pushed to revoke approval of the stand‑alone polio vaccine.
- The meeting became contentious, with sharp exchanges; Dr. Michael Osterholm called the vote a 'defining moment' and said federal health authorities can no longer be trusted on vaccines.
Trump signs off on nationwide vaccine schedule review as CDC withdraws infant Hep B guidance: 'Fast track'
New information:
- President Trump said he signed a presidential memorandum directing HHS to 'fast track' a comprehensive evaluation of U.S. childhood vaccine schedules and consider alignment with other countries.
- Trump publicly praised ACIP’s vote to end the universal Hepatitis B birth‑dose recommendation and criticized the current vaccine schedule.
- The White House did not immediately provide additional comment to Fox News Digital.
Republican Sen. Bill Cassidy slams change to hepatitis B vaccine guidance as "a mistake"
New information:
- Sen. Bill Cassidy criticized the ACIP change, calling it a 'mistake.'
- CBS frames the reaction in a segment with analysis by Dr. Jon LaPook.
RFK-appointed CDC panel drops hepatitis B vaccine at birth recommendation
New information:
- PBS adds on-the-record reaction from Dr. Paul Offit, who says he was invited to testify before ACIP but declined.
- Offit provides historical epidemiology: in the early 1990s an estimated 30,000 U.S. children under 10 had hepatitis B, about half not from mother-to-child transmission, and describes household transmission routes (e.g., shared personal items).
- Offit argues the birth-dose recommendation virtually eliminated hepatitis B in children under 10 and says reversing it 'puts children in harm's way.'
- PBS characterizes the new guidance as shifting to parent–physician consultation rather than a universal birth-dose mandate.
GOP senator calls CDC's hepatitis B vaccine change 'a mistake' that will make America sicker
New information:
- Sen. Bill Cassidy publicly urges the CDC’s acting director not to sign ACIP’s recommendation ending routine HBV newborn vaccination.
- Cassidy argues the birth-dose recommendation reduced newborn HBV infections from ~20,000 annually to fewer than 20 and warns cases could rise if the guidance changes.
- Cassidy labels ACIP 'totally discredited' and criticizes attorney Aaron Siri’s influence in vaccine debates.
CDC advisers vote to overturn decades-long policy on hepatitis B vaccine for infants
New information:
- NPR reports the panel voted 8–3 to recommend a hepatitis B birth dose only for babies of HBV‑positive mothers; those with negative or unknown maternal status should consult physicians.
- ACIP separately voted 6–4 with one abstention to recommend testing infants’ antibody levels after each shot to determine whether fewer than three doses are needed.
- CDC official Dr. Adam Langer cautioned that stopping at one or two doses would depart from evidence tested in three‑dose vaccine trials.
- Quotations add on‑the‑record dissent and support: Dr. Cody Meissner warned infections will rise if the change is finalized; Retsef Levi called it a “fundamental change” and said parents may delay; PIDS liaison Dr. Grant Paulsen questioned the rationale for changing a policy that has worked.
- Confirms the recommendation still requires approval by the acting CDC director.
RFK Jr.’s chosen vaccine advisers say not all babies need a hepatitis B shot at birth
New information:
- Names acting CDC director Jim O’Neill as the official who will decide whether to adopt the recommendation.
- Adds on‑the‑record criticism from Dr. William Schaffner calling the panel 'the group that can’t shoot straight.'
- Quotes ACIP member Vicky Pebsworth saying there was 'pressure from stakeholder groups' to revisit the policy.
- Notes Dr. Peter Hotez declined to present, saying ACIP has shifted away from science-based decision-making.
- Specifies that in June HHS Secretary Robert F. Kennedy Jr. fired the entire 17‑member ACIP and replaced it, including with several anti‑vaccine voices.
- Frames the move as a return to a strategy abandoned more than three decades ago and emphasizes CDC currently has no permanent director.
CDC panel votes to stop recommending birth dose of hepatitis B vaccine
New information:
- ACIP voted 8–2 to recommend delaying the hepatitis B vaccine birth dose until 2 months of age for infants born to mothers who test negative for hepatitis B.
- For infants of hepatitis B–negative mothers, the panel recommended individual decision‑making with a clinician on whether and when to administer a birth dose.
- Opposition noted from medical groups including the American Academy of Pediatrics, citing decades of data on safety and effectiveness and concern about increased risk.
- Panel composition noted: current ACIP members were appointed by HHS Secretary Robert F. Kennedy Jr.
- Named voices in the debate included Dr. Cody Meissner (opposed to the change) and Dr. Joseph Hibbeln; the meeting featured disputes over evidence and rapidly changing vote language.
- Recommendations now go to the CDC director for approval; state policies and insurer coverage could be affected if CDC adopts the change.
- No additional ACIP votes were scheduled in this meeting after the HepB decision.
WATCH LIVE: RFK’s CDC panel expected to vote on hepatitis B shot for newborns after delaying
New information:
- Article specifies that acting CDC director Jim O’Neill would make the final decision because the agency currently has no director.
- Names ACIP member Vicky Pebsworth, who said a work group was tasked in September with evaluating whether a birth dose is necessary when mothers test negative and cited the need to address stakeholder/parent dissatisfaction.
- Clarifies contemplated policy: a birth dose only for infants of hepatitis B–positive mothers, with other cases left to parent–physician decision-making.
- Notes meeting logistics: ACIP reconvenes Friday at 9 a.m. ET in Atlanta; PBS is streaming the session live.
CDC advisers delay planned vote on hepatitis B vaccine for infants
New information:
- ACIP postponed planned votes on changes to the universal newborn hepatitis B recommendation and rescheduled them for Friday due to confusion and late changes in the vote language.
- Voting member Dr. Joseph Hibbeln criticized shifting question wording, calling it a 'moving target.'
- FDA representative Dr. Tracy Beth Høeg questioned the need for a universal birth dose in low‑risk infants; Dr. Cody Meissner defended the current policy’s effectiveness.
- Adviser Robert Malone challenged Meissner’s statements as opinion; Meissner replied, 'These are facts, Robert.'
- Nonvoting medical‑society liaisons condemned the process as deviating from ACIP norms.
CDC panel to vote on hepatitis B vaccine for newborns
New information:
- ACIP will explicitly vote on whether to continue universal newborn hepatitis B vaccination at birth or delay the first dose.
- CDC/AAP data points: 99% decline in infant/child hepatitis B infections since 1991; an estimated 2.4 million people in the U.S. have HBV and about half are unaware.
- Effectiveness figures: birth dose within 24 hours is up to 90% effective at preventing mother-to-child transmission; full three-dose series confers ~98% immunity.
- Screening gap: about 16% of pregnant women are not screened for HBV, making the birth dose a critical safety net.
- 2021 outcomes: 17,827 births to HBV-positive mothers but only 17 reported neonatal transmissions, with the AAP crediting the birth dose.
- Context notes: HHS Secretary Robert F. Kennedy Jr. appointed current ACIP members; CBS flags his prior false claim linking the birth dose to autism.
Hepatitis B: What parents should know about the virus and the vaccine
New information:
- A new (preprint) analysis estimates delaying the Hep B birth dose by two months could cause at least 1,400 additional preventable infections each year; delaying until age 12 could cause at least 2,700 per year.
- Expert quotes (Dr. Andrew Pavia/IDSA) warning that rescinding the universal birth dose would be “extremely dangerous.”
- Additional context on non-sexual transmission risks in children (e.g., day care, shared razors/toothbrushes, surface contamination lasting up to seven days).
- Reference to President Trump’s suggestion to delay vaccination until age 12, contrasted with transmission risks in early childhood.
WATCH LIVE: RFK Jr.’s CDC panel to debate whether newborns should get lifesaving hepatitis B shot
New information:
- ACIP’s hepatitis B agenda item is set for a Dec. 4, 8 a.m. ET hearing with a live stream available.
- AP reports the HHS secretary’s advisory panel is expected to change the newborn hepatitis B recommendation, contradicting prior public-health guidance.
- The American Academy of Pediatrics (AAP), via Dr. Sean O’Leary, says it will continue to recommend the hepatitis B birth dose because it saves lives.
CDC's vaccine advisers meet to question long-used vaccines
New information:
- ACIP will meet Dec. 4–5 to reconsider fundamental elements of the childhood vaccine schedule and is expected to make a controversial change to infant hepatitis B immunization.
- ACIP’s chair was replaced this week; the new chair is Dr. Kirk Milhoan, a pediatric cardiologist affiliated with the Independent Medical Alliance.
- ACIP’s September meeting devolved into confusion and a scheduled vote on hepatitis B was tabled.
- NPR reports the CDC changed its stance last month on whether vaccines may cause autism, further eroding confidence among mainstream medical groups.
- ACIP has reduced longstanding collaboration with groups like AAP and relies less on CDC staff; AAP, AAFP and the University of Minnesota’s Vaccine Integrity Project have begun issuing independent recommendations, with some states following them.
- A new ACIP working group will present its first report scrutinizing the childhood vaccine schedule.
- Quotes included from Mary Holland (Children’s Health Defense) and Dr. Sean O’Leary (AAP infectious diseases committee chair) reflecting sharply divergent views.
Doctors warn delaying hepatitis B shot for newborns could revive a deadly threat
New information:
- Notes the ACIP panel considering the birth-dose recommendation is appointed by HHS Secretary Robert F. Kennedy Jr.
- Adds efficacy specifics: a hepatitis B birth dose given within 24 hours is up to 90% effective at preventing mother-to-child transmission; completing the 3-dose series confers ~98% immunity with protection lasting at least 30 years.
- Details Western Alaska outcomes: after targeted testing and vaccination campaigns, pediatric liver cancer has not been seen since 1995 and no infections are known in children under 30.
- Clarifies that maintaining the birth-dose recommendation preserves the broadest insurance coverage options; ACIP/CDC do not mandate vaccines and states control requirements.
- Documents RFK Jr.’s June podcast claims (autism link; hepatitis B not casually contagious) and counters with research that the virus can transmit via indirect contact and survive on surfaces for a week.